WO2008061647A8 - Use of a compound as vegf inhibitor - Google Patents
Use of a compound as vegf inhibitorInfo
- Publication number
- WO2008061647A8 WO2008061647A8 PCT/EP2007/009767 EP2007009767W WO2008061647A8 WO 2008061647 A8 WO2008061647 A8 WO 2008061647A8 EP 2007009767 W EP2007009767 W EP 2007009767W WO 2008061647 A8 WO2008061647 A8 WO 2008061647A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- agent
- vegf inhibitor
- vegf
- dimethoxybenzylideneamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is disclosed the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine or a pharmacologically acceptable salt thereof as an agent for use in the inhibition of Vascular Endothelial Growth Factor (VEGF). Such an agent is likely to be of application in the treatment or prevention of undesired blood vessel formation during tumour growth and/or in inflammatory conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0623381.1A GB0623381D0 (en) | 2006-11-23 | 2006-11-23 | Use of a compound as VEGF inhibitor |
| GB0623381.1 | 2006-11-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008061647A1 WO2008061647A1 (en) | 2008-05-29 |
| WO2008061647A8 true WO2008061647A8 (en) | 2008-11-27 |
Family
ID=37636386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2007/009767 Ceased WO2008061647A1 (en) | 2006-11-23 | 2007-11-12 | Use of a compound as vegf inhibitor |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0623381D0 (en) |
| WO (1) | WO2008061647A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| RU2012106467A (en) * | 2009-07-31 | 2013-09-10 | Анамар Аб | COMPOUNDS FOR TREATMENT OF INFLAMMATION |
| CN106488907B (en) * | 2014-07-02 | 2021-01-29 | 英费列特斯生命科学公司 | O-alkyl-benzylidene guanidine derivatives and their therapeutic use for the treatment of diseases associated with accumulation of misfolded proteins |
| ES2812800T3 (en) | 2014-07-02 | 2021-03-18 | Inflectis Bioscience | New therapeutic uses of benzylidenguanidine derivatives for the treatment of proteopathies |
| WO2019215470A1 (en) | 2018-05-09 | 2019-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| SE9604348D0 (en) * | 1996-11-26 | 1996-11-26 | Wapharm Ab | Use of hydroxyguanidines |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
-
2006
- 2006-11-23 GB GBGB0623381.1A patent/GB0623381D0/en not_active Ceased
-
2007
- 2007-11-12 WO PCT/EP2007/009767 patent/WO2008061647A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB0623381D0 (en) | 2007-01-03 |
| WO2008061647A1 (en) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008075068A3 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| WO2010021680A3 (en) | Inhibitors of beta-secretase | |
| WO2008076862A3 (en) | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors | |
| WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
| WO2012065958A9 (en) | Method of treating contrast-induced nephropathy | |
| WO2009005269A3 (en) | Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives | |
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| WO2010032875A3 (en) | Heterocyclic carboxamide compounds | |
| WO2011052923A3 (en) | Novel 1,6-disubstituted indole compounds as protein kinase inhibitors | |
| EP2607348A3 (en) | Plasminogen Activator Inhibitor-1 Inhibitor | |
| WO2007109251A3 (en) | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | |
| WO2007095618A3 (en) | Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine | |
| WO2009086426A3 (en) | Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction | |
| IL197934A (en) | Hydrobenzamide derivatives as inhibitors of hsp90 and uses thereof for treating disease conditions | |
| WO2006011631A3 (en) | Thiazole derivatives having vap-1 inhibitory activity | |
| TW200420549A (en) | Thiazole derivatives | |
| WO2007101232A3 (en) | Inhibition of jak2 as a treatment of pulmonary arterial hypertension | |
| BRPI1011804A2 (en) | pharmaceutical composition with improved solubility | |
| WO2008061647A8 (en) | Use of a compound as vegf inhibitor | |
| WO2008027013A3 (en) | Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer | |
| IL192600A0 (en) | Method of treating or preventing tissue damage caused by increased blood flow | |
| NZ592927A (en) | PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | |
| EA200900862A1 (en) | DERIVATIVES OF PROSTACYCLINE | |
| NZ624708A (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07819756 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07819756 Country of ref document: EP Kind code of ref document: A1 |